Ing Groep Nv Biogen Inc. Transaction History

Ing Groep Nv

$16.5 Billion
Q2 2024

A detailed history of Ing Groep Nv transactions in Biogen Inc. stock. As of the latest transaction made, Ing Groep Nv holds 24,595 shares of BIIB stock, worth $4.27 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

24,595

Previous 54,898 55.2%

Holding current value

$4.27 Million

Previous $11.8 Million 51.84%

% of portfolio

0.03%

Previous 0.08%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$190.52 - $236.72 $5.77 Million - $7.17 Million	-30,303 Reduced 55.2%	24,595 $5.7 Million
Q1 2024 May 10, 2024	BUY	$212.02 - $267.71 $1.15 Million - $1.45 Million	5,406 Added 10.92%	54,898 $11.8 Million
Q4 2023 Feb 08, 2024	BUY	$222.59 - $267.94 $114,856 - $138,257	516 Added 1.05%	49,492 $12.8 Million
Q3 2023 Oct 27, 2023	BUY	$253.3 - $285.89 $1.3 Million - $1.47 Million	5,128 Added 11.69%	48,976 $12.6 Million
Q2 2023 Aug 07, 2023	SELL	$275.25 - $318.06 $20.3 Million - $23.4 Million	-73,710 Reduced 62.7%	43,848 $12.5 Million
Q1 2023 May 09, 2023	BUY	$256.56 - $292.34 $13.3 Million - $15.1 Million	51,662 Added 78.4%	117,558 $32.7 Million
Q4 2022 Feb 10, 2023	BUY	$252.44 - $306.72 $8.06 Million - $9.79 Million	31,932 Added 94.02%	65,896 $18.2 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $416,247 - $573,967	-2,138 Reduced 5.92%	33,964 $9.07 Million
Q2 2022 Aug 08, 2022	BUY	$187.54 - $223.02 $798,732 - $949,842	4,259 Added 13.37%	36,102 $7.36 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $691,758 - $871,579	-3,570 Reduced 10.08%	31,843 $6.71 Million
Q4 2021 Feb 11, 2022	BUY	$223.92 - $287.77 $2.3 Million - $2.96 Million	10,278 Added 40.89%	35,413 $8.5 Million
Q3 2021 Nov 02, 2021	BUY	$282.99 - $369.05 $32,543 - $42,440	115 Added 0.46%	25,135 $7.11 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $1.28 Million - $2.05 Million	4,934 Added 24.56%	25,020 $8.66 Million
Q1 2021 May 12, 2021	SELL	$242.95 - $284.63 $29,396 - $34,440	-121 Reduced 0.6%	20,086 $5.62 Million
Q4 2020 Feb 11, 2021	BUY	$236.26 - $355.63 $1.58 Million - $2.38 Million	6,703 Added 49.64%	20,207 $4.95 Million
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $562,371 - $649,328	2,124 Added 18.66%	13,504 $3.83 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $1.79 Million - $2.37 Million	-6,927 Reduced 37.84%	11,380 $3.05 Million
Q1 2020 May 06, 2020	SELL	$268.85 - $341.04 $1.09 Million - $1.39 Million	-4,070 Reduced 18.19%	18,307 $5.79 Million
Q4 2019 Feb 10, 2020	BUY	$220.06 - $304.07 $190,792 - $263,628	867 Added 4.03%	22,377 $6.64 Million
Q3 2019 Nov 08, 2019	BUY	$217.44 - $243.88 $2.62 Million - $2.94 Million	12,049 Added 127.35%	21,510 $5.01 Million
Q2 2019 Aug 12, 2019	SELL	$219.29 - $241.72 $12.9 Million - $14.2 Million	-58,911 Reduced 86.16%	9,461 $2.21 Million
Q1 2019 May 13, 2019	BUY	$216.71 - $338.96 $1.21 Million - $1.89 Million	5,590 Added 8.9%	68,372 $16.2 Million
Q4 2018 Feb 13, 2019	BUY	$278.5 - $352.75 $4.41 Million - $5.59 Million	15,850 Added 33.77%	62,782 $18.9 Million
Q3 2018 Nov 06, 2018	BUY	$293.51 - $383.83 $5.76 Million - $7.53 Million	19,621 Added 71.84%	46,932 $16.6 Million
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $7.14 Million - $8.51 Million	-27,725 Reduced 50.38%	27,311 $7.93 Million
Q1 2018 May 07, 2018	BUY	$260.13 - $367.91 $36,938 - $52,243	142 Added 0.26%	55,036 $15.1 Million
Q4 2017 Feb 06, 2018	SELL	$307.64 - $344.58 $917,690 - $1.03 Million	-2,983 Reduced 5.15%	54,894 $17.5 Million
Q3 2017 Nov 08, 2017	BUY	$281.15 - $329.69 $16.3 Million - $19.1 Million	57,877	57,877 $18.1 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.

Account